A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Kowa Research Institute, Inc.
- Study ID
- NCT05403827
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- K-161 — DRUGK-161 Ophthalmic Solution
- Placebo — DRUGVehicle Solution
Study Details
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
Key Dates
- First listed
- Jun 3, 2022
- Start date
- Jul 3, 2022
- Status verified
- Jan 2025
- Primary completion
- Aug 25, 2023
- Completion
- Dec 5, 2023
Study Design
- Enrollment
- 644 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: K-161K-161 Ophthalmic Solution
- Placebo Comparator: PlaceboVehicle Solution
Primary Outcome Measure
Change in EDS (VAS) From Baseline to Day 85 [ Time Frame: Baseline to Day 85 ]
Locations (51)
Find similar trials in Birmingham, AL
By research site
The University of Alabama at Birmingham School of Optometry, Clinical Eye Research Center· Birmingham, ALTrinity Research Group· Dothan, ALCornea and Cataract Consultants of Arizona· Phoenix, AZCitrus Valley Eyecare / Premiere Practice Management, LLC· Covina, CAOrange County Ophthalmology Medical Group· Garden Grove, CAGlobal Research Management· Glendale, CA
Related Studies
- 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHDRecruiting · University of Maryland, Baltimore · Baltimore, Maryland